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CPAP for excessive sleepiness in elderly patients
Expansion of the ageing population has led to questions 
about the rationalisation of health-care support and the 
cost-eﬀ ectiveness ratio of all treatment approaches for 
elderly patients. Sleep-related breathing disorders are 
highly prevalent after age 65 years,1 and their treatment 
is a major reason for the increase in health-care 
spending. Obstructive sleep apnoea (OSA) syndrome is 
a well established risk factor for cardiovascular diseases 
in adults, but the deleterious eﬀ ect of OSA syndrome in 
elderly people remains controversial,2 and some authors 
have discussed the concept of so-called preconditioning 
with chronic intermittent hypoxia, meaning elderly 
apnoeic patients could have less chance of myocardial 
infarction.3 The unknown beneﬁ ts routinely oﬀ ered 
by the treatment of OSA syndrome in elderly patients 
should be taken into account by public authorities 
when planning resource allocation. However, the 
main symptom associated with sleep apnoea, diurnal 
sleepiness, seems to be costly and dangerous in this 
population4 and seems to be a valid target for the eﬃ  cacy 
of treatment of OSA syndrome in older people. 
In the PREDICT study published in The Lancet 
Respiratory Medicine, Alison McMillan and colleagues5 
show in a multicentre, randomised, two-parallel-group 
study of continuous positive airway pressure (CPAP) that 
this treatment signiﬁ cantly reduced daytime sleepiness 
in patients aged 65 years or older at 3-month and 1-year 
follow-up visits. The quality of work done by the authors 
should be emphasised. The magnitude of improvement 
is quite similar to that noted in younger adults, and 
this amplitude is well correlated with the average night 
duration use of CPAP.6 The short median duration of 
CPAP usage in the PREDICT study (1 h 52 min per night 
at 3 months and 2 h 22 min per night at 12 months) 
suggests a greater eﬃ  ciency of CPAP for patients with 
longer nightly CPAP use. A minimum duration of 5 h of 
daily use for patients should be insisted upon if CPAP is 
to have a substantial eﬀ ect on neurocognitive function.7 
The authors did not attempt to explain the important 
question of the beneﬁ cial role of CPAP on cardiovascular 
morbidity and mortality in patients aged 65 years or 
older. This treatment approach leads to a marginal 
reduction in health costs. During 1-year follow-up, CPAP 
does not seem to improve mood, cognitive function, 
or incidence of accidents. We should emphasise here 
that the study was not originally designed to address 
these issues, and thus, ﬁ rm conclusions could not be 
derived from these secondary endpoint analyses. In 
our opinion, the decrease in plasma LDL cholesterol 
is diﬃ  cult to explain by the nocturnal CPAP alone.8 
Somewhat surprisingly, the lower blood pressure noted 
in the group who received best supporting care can only 
encourage us to heavily emphasise advice on lifestyle 
(reducing physical inactivity, reducing salt intake, and 
improving medication adherence) when patients are 
seen in our sleep medicine clinics.9 The reported decrease 
of 3–4 mm Hg in blood pressure could be very proﬁ table 
in terms of health costs at the 10-year follow-up point.
Several criticisms can be made of this study. First is 
the use of the Epworth sleepiness scale to characterise 
the extent of daytime sleepiness; this questionnaire 
is sometimes not suitable for elderly patients because 
most are not able to answer all of the Epworth scale score 
items, thus this scale might underestimate sleepiness 
severity in older patients.10 However, signiﬁ cant and 
consistent improvements in the Oxford Sleep Resistance 
test reported in the CPAP group conﬁ rm an objective 
improvement in daytime sleepiness from use of CPAP. 
Additionally, a detailed comparative analysis of the 
macroarchitecture and microarchitecture of sleep in the 
two groups of patients is absent. In fact, sleep apnoea 
syndrome in elderly people is often entangled with 
other sleep diseases, and it would have been interesting 
to compare the improvement of the eﬀ ectiveness and 
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continuity of sleep in both groups. Finally, daytime 
sleepiness is usually present less often (and if present, 
is less severe) in elderly patients with OSA syndrome, 
and elderly patients can cope better with sleepiness 
symptoms because they are often not in full-time 
work. Older apnoeic patients screened and recruited 
in this study were far from representative of the 
whole panel of older apnoeic patients seen in routine 
clinical practice. Many elderly apnoeic patients have no 
daytime sleepiness and consult for other symptoms—
eg, nocturia, severe snoring, waking with feelings of 
choking, or minor memory complaints—or OSA is 
discovered by chance after onset of stroke or heart 
attack. It is diﬃ  cult to determine the beneﬁ t of CPAP in 
the non-sleepy elderly apnoeic patients complaining 
about non-speciﬁ c symptoms associated with 
unrefreshing sleep. In the study, the number of women 
is low, and thus the underrepresentation of women 
reduces the generalisation of the results obtained in 
men. We know that daytime sleepiness, according to an 
equivalent severity of apnoea or hypopnea, is often less 
severe in women than in men.1 This diﬀ erence in clinical 
presentation is important to consider in the detection 
and treatment of all apnoeic patients. 
The quality of the work in this study is remarkable 
and encourages continued high-quality controlled 
clinical trials in the specialty of sleep-related breathing 
disorders in elderly people; a disorder that can aﬀ ect a 
third of patients aged 68 years or older and that might 
signiﬁ cantly accelerate cognitive decline in undiagnosed 
and untreated patients.
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Dromedary MERS-CoV replicates in human respiratory tissues
Since its discovery in the autumn of 2012, Middle East 
respiratory syndrome coronavirus (MERS-CoV) has 
caused more than 800 laboratory-conﬁ rmed cases of 
human infection, with a case-fatality rate of about a 
third.1 Patients admitted to hospital with MERS are 
characterised by symptoms of severe pneumonia, 
often accompanied by renal failure. However, mild 
and asymptomatic infections have been reported, 
especially in secondary cases. Dromedary camels have 
been identiﬁ ed as the putative source of human MERS-
CoV infections, although nosocomial transmission 
is increasingly reported. So far, all cases of human 
MERS-CoV infection were identiﬁ ed in Middle Eastern 
countries, or in individuals who had recently travelled 
from that area.
At present, endeavours to control this emerging 
pathogen target two main eﬀ orts. First, identiﬁ cation 
of the source of zoonotic MERS-CoV infections 
might guide control strategies at the human–animal 
interface. Second, source and contact tracing in 
combination with hygiene and isolation measures will 
restrict human-to-human transmission of MERS-CoV. 
Although MERS-CoV is phylogenetically related to 
bat β-coronaviruses, epidemiological investigations 
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